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There are multiple neurological complications of cancer and its treatment. This study
assessed the utility of the novel non-invasive ophthalmic technique of corneal confocal
microscopy in identifying neuropathy in patients with upper gastrointestinal cancer before
and after platinum based chemotherapy. In this study, 21 subjects with upper gastrointesti-
nal (oesophageal or gastric) cancer and 21 healthy control subjects underwent assessment
of neuropathy using the neuropathy disability score, quantitative sensory testing for vibra-
tion perception threshold, warm and cold sensation thresholds, cold and heat induced pain
thresholds, nerve conduction studies and corneal confocal microscopy. Patients with gas-
tro-oesophageal cancer had higher heat induced pain (P = 0.04) and warm sensation (P =
0.03) thresholds with a significantly reduced sural sensory (P<0.01) and peroneal motor
(P<0.01) nerve conduction velocity, corneal nerve fibre density (CNFD), nerve branch den-
sity (CNBD) and nerve fibre length (CNFL) (P<0.0001). Furthermore, CNFD correlated sig-
nificantly with the time from presentation with symptoms to commencing chemotherapy (r =
-0.54, P = 0.02), and CNFL (r = -0.8, P<0.0001) and CNBD (r = 0.63, P = 0.003) were related
to the severity of lymph node involvement. After the 3rd cycle of chemotherapy, there was
no change in any measure of neuropathy, except for a significant increase in CNFL (P =
0.003). Corneal confocal microscopy detects a small fibre neuropathy in this cohort of
patients with upper gastrointestinal cancer, which was related to disease severity. Further-
more, the increase in CNFL after the chemotherapy may indicate nerve regeneration.
PLOS ONE | DOI:10.1371/journal.pone.0139394 October 2, 2015 1 / 9
a11111
OPEN ACCESS
Citation: Ferdousi M, Azmi S, Petropoulos IN,
Fadavi H, Ponirakis G, Marshall A, et al. (2015)
Corneal Confocal Microscopy Detects Small Fibre
Neuropathy in Patients with Upper Gastrointestinal
Cancer and Nerve Regeneration in Chemotherapy
Induced Peripheral Neuropathy. PLoS ONE 10(10):
e0139394. doi:10.1371/journal.pone.0139394
Editor: Soroku Yagihashi, Hirosaki University
Graduate School of Medicine, JAPAN
Received: June 16, 2015
Accepted: September 11, 2015
Published: October 2, 2015
Copyright: © 2015 Ferdousi et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: Data are available on
Figshare (DOI=http://dx.doi.org/10.6084/m9.figshare.
1449256).
Funding: The authors have no support or funding to
report.
Competing Interests: The authors have declared
that no competing interests exist.
Abbreviations: CIPN, Chemotherapy induced
peripheral neuropathy; CIP, Cold Induced Pain; CST,
Cold Sensation Threshold; CTCAE, Common
Introduction
Neurological complications of cancer include direct tumour compression or infiltration, para-
neoplastic neurological syndromes (PNS), metabolic and nutritional deficiencies and chemo-
therapy induced peripheral neuropathy (CIPN) [1]. CIPN has a detrimental impact on the
patients' quality of life [2], has limited treatment options [3] and may lead to chemotherapy
dose reduction or discontinuation [4]. Cisplatin and Oxaliplatin are known to cause problem-
atic dose limiting peripheral neuropathies, particularly in patients receiving standard of care
treatments for gastro-oesophageal cancers [5].
The aetiology of CIPN remains to be determined [1]. A recent study has shown that pacli-
taxel-induced neuropathy has a heritable component, driven in part by genes involved in axon
outgrowth [6]. Early objective detection of neuropathy is important to enable clinicians to
identify patients who may already have neuropathy and who may therefore be more likely to
develop CIPN to enable an alteration in chemotherapy doses. Currently physicians record the
patient’s subjective history of neurologic symptoms using the Common Terminology Criteria
of Clinical Adverse Events (CTCAE) [7]. A number of symptom and deficit based neuropathy
focused scales have been proposed for assessing chemotherapy induced neuropathy [8–10].
More accurate diagnostic tests include nerve conduction studies (NCS), quantitative sensory
testing (QST) and skin biopsy for measuring the intra epidermal nerve fibre density (IENFD)
[11]. However, NCS assesses large fibres only, QST is subjective and skin biopsy is invasive and
requires expertise for quantification. Alternatively, nerve morphology can be rapidly assessed
using in vivo corneal confocal microscopy (IVCCM), and over the past decade we have pio-
neered the use of this technique to assess peripheral neuropathy in a range of neuropathies
including diabetic neuropathy [12–14], Idiopathic small fibre neuropathy (ISFN) [15], Fabry’s
disease [16] and Charcot-Marie-Tooth Neuropathy Type 1 (CMT1A) [17]. Others have
deployed it in non-length dependent and autoimmune neuropathies [18, 19]. A recent experi-
mental study has shown a paclitaxel induced dose-dependent loss of small nerve fibres in both
the skin and cornea of mice [20]. To date there is one case report of a 75-year-old man with
metastatic colorectal carcinoma receiving capecitabine who developed CIPN, and CCM
showed increased beading, tortuosity and sprouting of the corneal nerves [21]. We have there-
fore undertaken a detailed study using CCM in patients with upper GI cancer before and after
receiving chemotherapy.
Methodology
This study was approved by the North Manchester Research Ethics Committee, and adhered to
the tenets of the Declaration of Helsinki. Patients were recruited from The Christie Hospital
Foundation Trust, Manchester, UK. Informed written consent was obtained from all the partic-
ipants. 21 patients scheduled to undergo either curative or palliative chemotherapy with Oxali-
platin or Cisplatin containing regimens were examined at baseline. Exclusion criteria were
other causes of neuropathy such as diabetes, deficiency of vitamin B12 or folate, autoimmune
disease and any history of systemic or ocular disease with corneal involvement. Only 13
patients were examined after 3 cycles of chemotherapy due to voluntary withdrawal of consent,
disease progression and disability or death.
Clinical and neurological examination
All study participants including 21 patients and 21 aged matched healthy controls underwent
assessment of Body Mass Index (BMI), glycated haemoglobin (HbA1c), serum B12 and folate
levels. Symptoms were assessed using the Neuropathy Symptom Profile (NSP) and the McGill
pain questionnaire pre and post treatment and NCI Common Terminology Criteria for
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Terminology Criteria of Clinical Adverse Events;
CCM, Corneal Confocal Microscopy; CNBD, Corneal
nerve branch density; CNFD, Corneal nerve fibre
density; CNFL, Corneal nerve fibre length; CNFT,
Corneal nerve fibre tortuosity; HbA1c, Haemoglobin
A1c; NCS, Nerve conduction studies; NDS,
Neuropathy Disability Score; NSP, Neuropathy
Symptom Profile; NCCA, Non-Contact Corneal
Aesthesiometry; PMNamp, Peroneal motor nerve
amplitude; PMNCV, Peroneal motor nerve conduction
velocity; SFN, Small fibre neuropathy; SD, Standard
Deviation; SSNamp, Sural sensory nerve amplitude;
SSNCV, Sural sensory nerve conduction velocity;
VPT, Vibration Perception Threshold; WIP, Warm
Induced Pain; WST, Warm Sensation Threshold.
Adverse Events (CTCAE) (Version 4) post treatment. Neurological deficits were evaluated
using the simplified neuropathy disability score (NDS). Vibration perception threshold (VPT)
was assessed using a Neuroesthesiometer (Horwell, Scientific Laboratory Supplies, Wilford,
Nottingham, UK) on the hallux of both feet, and cold and warm sensation threshold (CST &
WST); and cold and warm induced pain threshold (CIP &WIP) were assessed with a TSA-II
NeuroSensory Analyser (Medoc Ltd., Ramat-Yishai, Israel) on the dorsolateral aspect of the
left foot. Sural sensory nerve amplitude (SSNamp), sural sensory nerve conduction velocity
(SSNCV), peroneal motor nerve amplitude (PMNamp) and peroneal motor nerve conduction
velocity (PMNCV) were assessed using a Dantec “Keypoint” system (Dantec Dynamics Ltd,
Bristol, UK).
Corneal assessment
Corneal sensitivity was measured using non-contact corneal aesthesiometry (NCCA) [22]
(Glasgow Caledonian University, Glasgow, Scotland, UK). Corneal imaging was undertaken
using a laser CCM (Heidelberg Retinal Tomograph III Rostock Cornea Module HRT III RCM;
Heidelberg Engineering GmbH, Heidelberg, Germany) according to our established protocol
[23]. Six images (3 from each eye) from the corneal sub-basal nerve plexus, taking into account
the depth, contrast and position from the centre of cornea were exported and analysed by a sin-
gle experienced examiner using purpose-designed software (CCMetrics (MA Dabbah; Imaging
Science and Biomedical Engineering, University of Manchester, Manchester, UK)) in a masked
fashion [24]. The outcome measures from these 6 images were averaged and used for statistical
analysis. Corneal nerve morphological parameters included corneal nerve fibre density
(CNFD)—number of main nerve fibres/mm2; corneal nerve branch density (CNBD)—number
of branch points on the main nerves/mm2; and corneal nerve fibre length (CNFL)—total length
of nerves mm/mm2.
Statistical analysis
IBM SPSS v19.0 (Chicago, IL, USA) for Windows was used to compute the results. All the data
were expressed as Mean ± SD and analysis included descriptive and frequency statistics. Inde-
pendent sample t tests (Mann-Whitney U test for non-parametric) were used to evaluate
between group differences. Paired sample t tests (Wilcoxon for non-parametric) were used to
evaluate differences between patients at baseline and follow up. One-way ANOVA with Bon-
feroni adjustment was used to evaluate between group differences. The association between the
corneal nerve morphological parameters and clinical findings was assessed using the Pearson
correlation coefficient (Spearman for non-parametric). Pearson’s Chi-square (χ2) test of inde-
pendence and a Fisher’s Exact test were used to evaluate the association between the categorical
variables. For all the comparisons, a P< 0.05 was considered significant. The data used for sta-
tistical analysis in this study can be found at http://dx.doi.org/10.6084/m9.figshare.1449256.
Results
Baseline
21 subjects (oesophageal cancer (n = 12), gastric cancer (n = 6), gastro-oesophageal junction
cancer (n = 3) with (n = 15) and without (n = 6) metastases and 21 age and gender matched
healthy control subjects were assessed. The clinical and demographic characteristics of patients
and healthy controls are summarised in Table 1. There was no significant difference in age,
BMI or alcohol and cigarette consumption between groups. HbA1c was significantly lower
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(P<0.05), B12 (P<0.05) was higher and folate (P<0.05) was lower compared to controls, how-
ever all values were within the normal range.
Neuropathy findings are summarised in Table 2. The HIP (P = 0.04) and WST (P = 0.03)
were significantly higher and SSNCV and PMNCV were significantly (P = 0.01) lower, with no
difference in the NDS, VPT, CST, CIP, SNamp, PMNamp or corneal sensation between
patients and control subjects. However, CNFD (P<0.0001), CNBD (P<0.0001) and CNFL
(P<0.0001) were significantly lower in patients compared to control subjects. Furthermore,
CNFD correlated significantly with the time from presentation with symptoms to the time
taken to receive the first cycle of chemotherapy (r = -0.54, P = 0.02). There were also highly sig-
nificant correlations between CNBD (r = -0.8, P<0.0001) and CNFL (r = -0.63, P = 0.003) with
the number of lymph nodes (>1cm) involved. There was no significant correlation between
corneal nerve morphology and the type or stage of cancer, or the presence of metastases.
Follow up
Of the 13 patients who attended for the follow up, eight received 3 cycles of Oxaliplatin con-
taining regimes [EOX regimes; Oxaliplatin (130mg/m2), Epirubicin and Capecitabine] and five
received 3 cycles of Cisplatin containing regimes [ECX regimes (n = 3); Cisplatin (60 mg/m2),
Epirubicin and Capecitabine] and [CXH regimes (n = 2); Cisplatin (80mg/m2), Capecitabine
and Herceptin]. Dose intensity for all 13 patients was maintained without any dose reductions
or dose delays. 8/13 patients developed grade 1 symptomatic paraesthesia on CTCAE criteria.
This was significantly higher in the patients who received Oxaliplatin compared to Cisplatin
containing regimens (78% vs. 20%, P = 0.03) (S1 Table). There were no significant difference
for any baseline or follow up measure of neuropathy between patients who did and did not
develop grade 1 symptomatic paraesthesia on CTCAE criteria (S2 Table).
Table 1. Clinical and demographic characteristics in patients with upper GI cancer and agematched
healthy controls.
Parameters Control Patients
Number (female/male) 21(2/20) 21(1/20)
Age (Years) 60.2±8.7 63.8±10.0
BMI (kg/m2) 27.4±4.3 27.0±6.4
Alcohol consumption (units per week) 6.7±9.2 14.4±15.3
Smoking (cigarettes per day) 0.9±3.0 4.5±7.9
HbA1c (mmol/mol) 39.7±2.9 34.5±6.1#
Serum B12 (ng/l) 245.6±77.4 668.2±383.2#
Serum Folate (ug/L) 10.3±5.6 2.7±0.58#
Anatomy (GAST/OES/GOJ) - (6/12/3)
Histology (ADENO/SQ) - (15/6)
Node - 1.3±0.9
Metastases (present/absent) - (15/6)
Stage - 3.5±0.8




Gastric (GAST), Oesophageal (OES); Gastro oesophageal junction (GOJ); Adenocarcinoma (ADENO);
Squamous cell carcinomas (SQ).
doi:10.1371/journal.pone.0139394.t001
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There was no change in the modified NDS, VPT, CST, CIP, WIP, SNamp, SSNCV,
PMNamp, PMNCV or corneal sensation, at follow up (Table 3). However, all CCM parameters
increased at follow up and this was significant for CNFL (P = 0.003) (Fig 1). Patients who
received Cisplatin or Oxaliplatin showed an increase in CNFL, which was significant in those
receiving Oxaliplatin (P = 0.03) (S1 Table). The increase in CNFL showed a significant inverse
correlation with the total dose of Cisplatin (r = -0.8, P = 0.05). All patients showed an increase
in corneal nerve fibre parameters at follow up except the patients with liver metastases who
showed a reduction in CNFD.
Discussion
We provide the first report of a detailed study relating CCM to clinical and neurological evalua-
tion in patients with upper GI cancer before and after platinum based chemotherapy. We show
no abnormality in a range of established measures of neuropathy including vibration and cold
perception as well as cold and heat induced pain thresholds in patients with upper GI cancer.
The sural sensory and peroneal motor nerve conduction velocity and warm sensation and heat
induced pain threshold demonstrated a mild deficit and an abnormal warm detection thresh-
old has been reported previously in patients with germ cell cancer prior to commencing cis-
platin and vinblastine [25]. Neuropathy can be identified clinically in 10–15% and using
Table 2. Baseline assessment of neuropathy in patients with upper GI cancer and agematched
healthy controls.
Parameters Control Patients
NSP (0–38) 0.67±1.06 0.83±1.7
McGill pain index (0–5) 0.29±0.96 0.12±0.5
NDS (0–10) 0.84±1.16 1.39±2.09
VPT (volts) 9.91±6.24 13.9±10.8
CST (°C) 27.99±2 26.8±2.1
WST (°C) 37.8±2.3 39.6±2.3#
CIP (°C) 13.01±8.72 10.1±8.1
HIP (°C) 43.39±10.33 46.8±2.8#
SSNCV (m/s) 48.14±3.12 44.1±6.3*
SSNamp (μA) 12.39±6.59 9.68±4.6
PMNCV (m/s) 46.04±3.62 42.7±3.8*
PMNamp (mV) 4.97±2.32 3.8±2.3
NCCA (mbars) 0.64±0.36 0.61±0.36
CNFD (no./mm2) 37.13±6.28 25.34±4.85$
CNBD (no./mm2) 98.43±33.2 50.84±28.38$
CNFL (mm/mm2) 26.82±4.27 18.08±3.62$




NSP (Neuropathy Symptom Proﬁle), NDS (Neuropathy Disability Score), VPT (Vibration perception
threshold), CST (Cold Sensation Threshold), WST (Warm Sensation Threshold), CIP (Cold Induced Pain),
HIP (Heat Induced Pain), SSNCV (Sural Sensory Nerve Conduction Velocity), SSNamp (Sural Sensory
Nerve Amplitude), PMNCV (Peroneal Motor Nerve Conduction Velocity), PMNamp (Peroneal Motor Nerve
Amplitude), NCCA (Non-Contact Corneal Aesthesiometer), CNFD (Corneal Nerve Fibre Density), CNBD
(Corneal Nerve Branch Density), CNFL (Corneal Nerve Fibre Length), no. (number).
doi:10.1371/journal.pone.0139394.t002
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electrodiagnostic testing in 35–50% of patients with cancer [26]. We now show that CCM
detects a marked reduction in corneal nerve morphological parameters in the cohort of patients
with upper GI cancer. Furthermore, this reduction was related to the number of abnormal
regional lymph nodes and the duration from presentation with symptoms to commencing
treatment. Whilst the severity of corneal nerve damage was not related to the histological type
or presence and site of metastases, there was an association with the prevalence of metastases
and increased mortality, presumably due to more advanced disease.
In the current study, all patients underwent curative-intent or palliative chemotherapy with
Cisplatin or Oxaliplatin, which are the standard of care treatments for gastro-esophageal can-
cers [27]. However, they cause unpredictable neurotoxicity [28] which can be debilitating [1]
and refractory to treatment [3, 25]. In the current study Cisplatin and Oxaliplatin containing
regimens caused symptomatic neuropathy (CTCAE>1) in 61.5% of patients. The underlying
mechanistic basis for these neuropathic symptoms is unclear. Thus Cisplatin treated patients
have previously shown no abnormality in cold pain thresholds [29]. Whilst a loss of large fibres
has been reported in the sural nerve of 3 patients treated with high dose platinum compounds,
unmyelinated axons that actually mediate pain were not assessed [30].
Painful neuropathy has been attributed to regeneration and sprouting of small fibres
recently in experimental models of pain [31] and in patients with diabetic neuropathy [32].
Perhaps of relevance, a recent study has shown that paclitaxel-induced neuropathy has a heri-
table component, driven in part by genes involved in axonal outgrowth [6]. And a recent case
Table 3. Demographic characteristics and clinical findings of the patients with upper GI cancer before
and after chemotherapy.
Parameters Baseline (13) Follow up (13)
NSP 0.42±0.66 1.91±3.39
NDS (0–10) 0.75±1.71 0.17±0.57
McGill pain index (0–5) 0.17±0.57 0.45±1.5
VPT (volts) 14.04±12.14 15.12±11.62
CST (°C) 26.42±2.27 24.56±8.04
WST (°C) 40.00±2.52 40.06±6.71
CIP (°C) 9.00±6.20 9.40±10.63
HIP (°C) 47.92±1.78 48.2±1.5
SSNCV (m/s) 42.70±7.11 44.6±5.7
SSNamp (μA) 9.39±4.41 10.8±4.4
PMNCV (m/s) 41.40±3.53 43.7±4.4
PMNamp (mV) 3.6±1.95 3.5±2.3
NCCA (mbars) 0.53±0.33 0.65±0.57
CNFD (no./mm2) 26.6±4.8 28.5±7.5
CNBD (no./mm2) 54.25±25.54 83.7±75.6
CNFL (mm/mm2) 18.76±3.67 22.0±6.8#
All data presented as Mean ± SD
#P<0.05.
NSP (Neuropathy Symptom Proﬁle), NDS (Neuropathy Disability Score), VPT (Vibration perception
threshold), CST (Cold Sensation Threshold), WST (Warm Sensation Threshold), CIP (Cold Induced Pain),
HIP (Heat Induced Pain), SSNCV (Sural Sensory Nerve Conduction Velocity), SSNamp (Sural Sensory
Nerve Amplitude), PMNCV (Peroneal Motor Nerve Conduction Velocity), PMNamp (Peroneal Motor Nerve
Amplitude), NCCA (Non-Contact Corneal Aesthesiometer), CNFD (Corneal Nerve Fibre Density), CNBD
(Corneal Nerve Branch Density), CNFL (Corneal Nerve Fibre Length), no. (number).
doi:10.1371/journal.pone.0139394.t003
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report has shown corneal nerve fibre sprouting in a patient with CIPN [21]. Indeed we now
show that patients who develop CIPN show an increase in corneal nerve fibre length, which
may be consistent with nerve regeneration. These findings are also in line with a previously
published study, which showed that intra epidermal nerve fibre density was increased signifi-
cantly in patients 6 months after chemotherapy [33].
A limitation of this study is the small number of patients attending the follow up visit which
may have resulted in bias, but this is due to the high morbidity and mortality from this type of
cancer. However, we believe our data are the first to show evidence of a small fibre neuropathy
in patients with upper GI cancer, which relates to the burden of disease. The observation that
CNFL was increased may provide novel insights into the underlying pathology of CIPN. Fur-
ther studies assessing a larger group of patients, at an earlier time point and for a longer follow
up period are warranted to explore the relevance of an increase in CNFL in relation to nerve
regeneration. These data provide further support for the use of CCM as a rapid non-invasive
means to image small nerve fibre damage and repair in a range of peripheral neuropathies.
Supporting Information
S1 Table. Demographic characteristics and clinical findings of the patients with upper GI
cancer grouped in relation to the type of chemotherapy agent. All data are presented as
Mean ± SD. Statistically significant difference compared to baseline visit, P<0.05.
(PDF)
S2 Table. Clinical findings and corneal nerve fibre parameters at baseline and follow che-
motherapy in patients showing no difference between patients with (+ve) and without (-ve)
symptomatic paraesthesia on the CTCAE criteria.
(PDF)
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